STVN · earnings call history
Stevanato Group Q2 FY26 — Strong Biologics & HVS Growth, Alina Pen Approval
Read the briefStevanato Group Q1 FY26 — Strong BDS Growth Driven by GLP-1s and Capacity Expansion
Read the briefStevanato Group Q4 FY25 — Strong High-Value Solutions Growth and GLP-1 Tailwinds
Read the briefBrowse all US companies on the earnings-call register.